Non sedating oral antihistamine 121phone chat com

22 Jan

Research into aspects of pharmacokinetics and efficacy and adverse effect profiles of bilastine in children under 12 years of age is needed as are dose-response assessments and studies planned rigorously with the aim of assessing quality of life effects.

Therefore, the launch of a recently developed non-sedating oral antihistamine, bilastine, attracts attention [3].

Bilastine does not undergo any significant metabolization.

Approximately, 95% is excreted intact in faeces (67%) or in urine (33%) [11].

Bilastine does not have any impact on the P450 (CYP) enzyme system of the liver, and there is no evidence of interaction with other drugs except that there is an increased uptake of bilastine when it is taken concomitantly with ketoconazole, erythromycin, or diltiazem [11].

This has been explained by probable interactions with intestinal transporters.